<DOC>
	<DOCNO>NCT01083810</DOCNO>
	<brief_summary>Long term observation patient lopinavir/ritonavir contain therapy</brief_summary>
	<brief_title>Evaluation Kaletra Therapy Over Long-term</brief_title>
	<detailed_description>Three five year observation lopinavir/ritonavir therapy . Reporting group 1 ) therapy-naïve patient ( 144 week ) , 2 ) therapy-experienced protease inhibitor naïve patient ( 240 week , ) 3 ) non-B subtype infect patient ( 240 week ) . These three group participant HIV-1 infection first register three different study : KAL1RO ( study , NCT01083810 , n=137 ) , KAL2RO /KAL5RO ( NCT01083836 , n=92 ) , KAL6RO ( NCT01081470 , n=55 ) reconcile KAL1RO ( NCT01083810 ) single study three report group .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patients infect HIV1 Age great equal 18 year describe SmPC ( summary product characteristic ) time prescription</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Infection</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Resistance</keyword>
	<keyword>Mutations</keyword>
	<keyword>alternative Therapy regimen</keyword>
</DOC>